SCHEMBL5457912

SCHEMBL5457912

CCOc1ccccc1NC(=O)Nc1ccc(N2CCN(C(=O)Nc3ccccc3C)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.55
NPC1 O15118 4/20 0.55
MEN1 O00255 4/20 0.55
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 2/20 0.55
GAA P10253 1/20 0.54
MAPT P10636 5/20 0.53
RAB9A P51151 3/20 0.53
TP53 P04637 1/20 0.52
POLB P06746 1/20 0.52
BLM P54132 1/20 0.52
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPK1 P28482 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5462591 0.92 MAPT (0.49) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5455735 0.92 MAPT (0.50) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5465117 0.87 KMT2A (0.61) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5464810 0.83 KMT2A (0.54) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5462055 0.82 NAMPT (0.58) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5460880 0.82 MAPT (0.49) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5460920 0.82 KMT2A (0.56) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5455863 0.81 KMT2A (0.62) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5455945 0.81 MAPT (0.57) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2
SCHEMBL5455975 0.81 MAPT (0.58) KMT2ANPC1MEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 KMT2A 1350/4885NPC1 1089/4885MEN1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.